Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia

Oncogene

Volumn 25, Issue 3, 2006, Pages 349-358

  Cesaire R ^a   Oliere S ^b,c   Sharif Askari, E ^b,c   Loignon, M ^b,c   Lezin A ^a   Olindo, S ^a   Panelatti, G ^a   Kazanji, M ^d   Aloyz, R ^b,c   Panasci, L ^b,c   Bell, J C ^e   Hiscott, J ^b,c  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE FORT DE FRANCE   (France)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d INSTITUT PASTEUR DE LA GUYANE   (French Guiana)

^e OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Apoptosis; ATL; HAM TSP; HTLV 1; Oncolysis; VSV

Indexed keywords

MONOCLONAL ANTIBODY CD28; MONOCLONAL ANTIBODY CD3; ONCOLYTIC VIRUS;

ARTICLE; CANCER PATIENT; CD4+ T LYMPHOCYTE; CELL MEMBRANE PERMEABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOLYSIS; EX VIVO STUDY; GENETIC DISORDER; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; LEUKEMIA CELL; PRIORITY JOURNAL; SAMPLE; SPASTIC PARESIS; SPINAL CORD DISEASE; T CELL LEUKEMIA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL; VESICULAR STOMATITIS VIRUS; VIRUS INFECTION; VIRUS REPLICATION;

HUMAN T-LYMPHOTROPIC VIRUS 1; VESICULAR STOMATITIS VIRUS;

EID: 30944442855     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209055     Document Type: Article

References (56)

1. Balachandran S, Barber GN. (2000). IUBMB Life 50: 135-138.
2. Balachandran S, Barber GN. (2004). Cancer Cell 5: 51-65.
3. Balachandran S, Porosnicu M, Barber GN. (2001). J Virol 75: 3474-3479.
4. Bazarbachi A, Ghez D, Lepelletier Y, Nasr R, De The H, El Sabban ME et al. (2004). Lancet Oncol 5: 664-672.
5. Belkowski LS, Sen GC. (1987). J Virol 61: 653-660.
6. Bell JC, Garson KA, Lichty BD, Stojdl DF. (2002). Curr Gene Ther 2: 243-254.
7. Caligaris-Cappio F. (2003). Br J Haematol 123: 380-388.
8. Cavrois M, Gessain A, Wain-Hobson S, Wattel E. (1996). Oncogene 12: 2419-2423.
9. Chiocca EA. (2002). Nat Rev Cancer 2: 938-950.
10. Desforges M, Despars G, Berard S, Gosselin M, McKenzie MO, Lyles DS et al. (2002). Virology 295: 63-73.
11. Durbin JE, Hackenmiller R, Simon MC, Levy DE. (1996). Cell 84: 443-450.
12. Eastman A, Rigas JR. (1999). Semin Oncol 26: 7-16.
13. Ebert O, Shinozaki K, Huang TG, Savontaus MJ, Garcia-Sastre A, Woo SL. (2003). Cancer Res 63: 3605-3611.
14. Fernandez M, Porosnicu M, Markovic D, Barber GN. (2002). J Virol 76: 895-904.
15. Franchini G, Nicot C, Johnson JM. (2003). Adv Cancer Res 89: 69-132.
16. Gadaleta P, Vacotto M, Coulombie F. (2002). Virus Res 86: 87-92.
17. Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A et al. (1985). Lancet 2: 407-410.
18. Grigera PR, Garcia-Briones M, Periolo O, la Torre JL, Wagner RR. (1996). J Virol 10: 8492-8501.
19. Gromeier M, Wimmer E. (2001). Curr Opin Mol Ther 3: 503-508.
20. Hawkins LK, Lemoine NR, Kirn D. (2002). Lancet Oncol 3: 17-26.
21. Hinuma Y, Komoda H, Chosa T, Kondo T, Kohakura M, Takenaka T et al. (1982). Int J Cancer 29: 631-635.
22. Hobbs JA, Hommel-Berrey G, Brahmi Z. (2003). Hum Immunol 64: 82-92.
23. Hobbs JA, Schloemer RH, Hommel-Berrey G, Brahmi Z. (2001). Virus Res 80: 53-65.
24. Huang TG, Ebert O, Shinozaki K, Garcia-Sastre A, Woo SL. (2003). Mol Ther 8: 434-440.
25. Kirn D, Martuza RL, Zwiebel J. (2001). Nat Med 7: 781-787.
26. Kopecky SA, Lyles DS. (2003). J Virol 77: 5524-5528.
27. Kopecky SA, Willingham MC, Lyles DS. (2001). J Virol 75: 12169-12181.
28. Lichty BD, Stojdl DF, Taylor RA, Miller L, Frenkel I, Atkins H et al. (2004). Hum Gene Ther 15: 821-831.
29. Linge C, Gewert D, Rossmann C, Bishop JA, Crowe JS. (1995). Cancer Res 55: 4099-4104.
30. Maruyama M, Shibuya H, Harada H, Hatakeyama M, Seiki M, Fujita T et al. (1987). Cell 48: 343-350.
31. Matin SF, Rackley RR, Sadhukhan PC, Kim MS, Novick AC, Bandyopadhyay SK. (2001). Cancer Res 61: 2261-2266.
32. Matsuoka M. (2003). Oncogene 22: 5131-5140.
33. Meinhardt G, Wendtner CM, Hallek M. (1999). J Mol Med 77: 282-293.
34. Mortreux F, Gabet AS, Wattel E. (2003). Leukemia 17: 26-38.
35. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM et al. (1994). Science 264: 1918-1921.
36. Na S, Chuang TH, Cunningham A, Turi TG, Hanke JH, Bokoch GM et al. (1996). J Biol Chem 271: 11209-11213.
37. Nguyen JT, Wells JA. (2003). Proc Natl Acad Sci USA 100: 7533-7538.
38. Norman KL, Farassati F, Lee PW. (2001). Cytokine Growth Factor Rev 12: 271-282.
39. Obuchi M, Fernandez M, Barber GN. (2003). J Virol 77: 8843-8856.
40. Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A et al. (1986). Lancet 1: 1031-1032.
41. Satoh M, Toma H, Sugahara K, Etoh K, Shiroma Y, Kiyuna S et al. (2002). Oncogene 21: 2466-2475.
42. Sharif-Askari E, Alam A, Rheaume E, Beresford PJ, Scotto C, Sharma K et al. (2001). EMBO J 20: 3101-3113.
43. Shimoyama M. (1991). Br J Haematol 79: 428-437.
44. Steele TA. (2000). Proc Soc Exp Biol Med 223: 118-127.
45. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N et al. (2000). Nat Med 6: 821-825.
46. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S et al. (2003). Cancer Cell 4: 263-275.
47. Sun WH, Pabon C, Alsayed Y, Huang PP, Jandeska S, Uddin S et al. (1998). Blood 91: 570-576.
48. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H et al. (2003). Nature 424: 516-523.
49. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. (1977). Blood 50: 481-492.
50. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace Jr AJ, Kohn KW et al. (1997). Science 275: 343-349.
51. Wolf BB, Green DR. (1999). J Biol Chem 274: 20049-20052.
52. Wolf BB, Schuler M, Echeverri F, Green DR. (1999). J Biol Chem 274: 30651-30656.
53. Woo M, Hakem R, Soengas MS, Duncan GS, Shahinian A, Kagi D et al. (1998). Genes Deo 12: 806-819.
54. Wu JT, Byrne HM, Kirn DH, Wein LM. (2001). Bull Math Biol 63: 731-768.
55. Yasunaga J, Matsuoka M. (2003). Int J Hematol 78: 312-320.
56. Yoshida M. (2001). Annu Rev Immunol 19: 475-496.